

PTO/SB/30 (09-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Request For Continued Examination (RCE) Transmittal

Address to:
MS RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Application Number	09/514,312	
Filing Date	February 28, 2000	
First Named Inventor	Takahide Kasai	
Art Unit	1615	
Examiner Name	Liliana Di Nola Baron	
Attorney Docket No.	31671-157328	

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.

Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application.

8, 1995, or to any design application.					
Submission required under 37 CFR 1.114 Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).					
a. Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.					
i. Consider the arguments in the Appeal Brief or Reply Brief previously filed on					
ii. Other					
b. x Enclosed					
i. X Amendment/Reply iii. Information Disclosure Statement (IDS)					
Declaration #1 Under 37 C.F.R. 1.132 (2 pages), with Figures 1, 2, and 3 (3 pages) attached; and Declaration #2 Under 37 C.F.R. 1.132 (4 pages). II. V Copy of Kasai et al., "Application of acid-treated yeast cell wall (AYC) as a pharmaceutical additive," International Journal of Pharmaceuticals 204:53-59 (2000).					
Miscellaneous Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)					
b. Other					
3. Fees The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.					
The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No					
i. X RCE fee required under 37 CFR 1.17(e)					
ii. X One Month Extension of time fee (37 CFR 1.136 and 1.17)					
iii. Other					
b. Check number 602822 in and check number 603157 in the amount of \$\frac{5770.00}{2} amount of \$\frac{110.00}{2} enclosed.					
c. Payment by credit card (Form PTO-2038 enclosed)					
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED					
Name (Print/Type) Nancy J. Axelrod Registration No. (Attorney/Agent) 44,014					
Signature Name Axund Date May 26, 2004					
542725v1					

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1615

Examiner: Dr. Liliana Di Nola-Baron

In Re PATENT APPLICATION OF

Applicants	:	Takahide KASAI et al.)
Appln. No. : 09/514,312		09/514,312)))
Conf. No.	:	8281) <u>REPLY</u>)
Filed	:	February 28, 2000))
For	:	COATED MATERIAL AND PROCESS FOR PRODUCING THE COATED MATERIAL (As amended)) 26694) U.S. PATENT AND TRADEMARK OFFICE)
Atty. Dkt.	:	31671-157328))

MAIL STOP RCE

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants have filed a request for continuing examination (RCE) in the above-referenced application. In response to the outstanding Office Action, dated August 26, 2003, in this application, please amend the application as indicated below and consider the remarks which follow.

Amendments to the Specification begin on page 2 of this paper.

Remarks/Arguments begin on page 5 of this paper.

05/27/2004 EFLORES 00000121 09514312

02 FC:1251

110.00 OP